Meeting News Coverage

Speaker: Base AMD treatment decisions on available medical evidence

KOLOA, Hawaii — As-needed administration of anti-VEGF provides durable results with less frequent dosing, a speaker said here, and ‘one dosing regimen does not fit all patients.’

“Today in 2014, there are many AMD treatments to choose – ranibizumab, bevacizumab and aflibercept. How do we choose?” Diana V. Do, MD, Director of the Truhlsen Eye Institute in Omaha, Nebraska, asked at Retina 2014.

Diana V. Do

Examining the highlights of the HARBOR trial, which studied as-needed dosing of ranibizumab, Do said, “The number one thing I learned from the HARBOR trial is that PRN treatment does not equate to progressive retinal neglect when patients are followed closely with spectral domain OCT.”

“PRN administration provides durable results with less frequent dosing,” she said. “And patients should be assessed regularly with spectral domain OCT to achieve optimal acuity outcomes.”

Among lessons learned about aflibercept, Do said that a small subpopulation of patients dosed bimonthly who have persistent fluid may benefit from more frequent dosing of the drug. Furthermore, in clinical practice, reports suggest that ranibizumab and bevacizumab suboptimal responders may respond to aflibercept, she said.

“Retina specialists should evaluate the medical evidence available to make the best recommendation for their individual patient,” Do said. —by Patricia Nale

Disclosure: Do has received research funding from Genentech and Regeneron.

KOLOA, Hawaii — As-needed administration of anti-VEGF provides durable results with less frequent dosing, a speaker said here, and ‘one dosing regimen does not fit all patients.’

“Today in 2014, there are many AMD treatments to choose – ranibizumab, bevacizumab and aflibercept. How do we choose?” Diana V. Do, MD, Director of the Truhlsen Eye Institute in Omaha, Nebraska, asked at Retina 2014.

Diana V. Do

Examining the highlights of the HARBOR trial, which studied as-needed dosing of ranibizumab, Do said, “The number one thing I learned from the HARBOR trial is that PRN treatment does not equate to progressive retinal neglect when patients are followed closely with spectral domain OCT.”

“PRN administration provides durable results with less frequent dosing,” she said. “And patients should be assessed regularly with spectral domain OCT to achieve optimal acuity outcomes.”

Among lessons learned about aflibercept, Do said that a small subpopulation of patients dosed bimonthly who have persistent fluid may benefit from more frequent dosing of the drug. Furthermore, in clinical practice, reports suggest that ranibizumab and bevacizumab suboptimal responders may respond to aflibercept, she said.

“Retina specialists should evaluate the medical evidence available to make the best recommendation for their individual patient,” Do said. —by Patricia Nale

Disclosure: Do has received research funding from Genentech and Regeneron.

    See more from Hawaiian Eye/Retina Meeting